These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

274 related articles for article (PubMed ID: 17322538)

  • 1. Clairvoyance or reliable prediction of the future?
    van Zandwijk N; van de Vijver MJ
    Ann Oncol; 2007 Mar; 18(3):407-8. PubMed ID: 17322538
    [No Abstract]   [Full Text] [Related]  

  • 2. Time for molecularly targeted maintenance therapy for non-small-cell lung cancer?
    Stinchcombe TE; Ramalingam SS
    Lancet Oncol; 2010 Jun; 11(6):500-1. PubMed ID: 20493770
    [No Abstract]   [Full Text] [Related]  

  • 3. NSCLC drug targets acquire new visibility.
    Friedrich MJ
    J Natl Cancer Inst; 2011 Mar; 103(5):366-7. PubMed ID: 21357596
    [No Abstract]   [Full Text] [Related]  

  • 4. Personalized medicine and inhibition of EGFR signaling in lung cancer.
    Gazdar AF
    N Engl J Med; 2009 Sep; 361(10):1018-20. PubMed ID: 19692681
    [No Abstract]   [Full Text] [Related]  

  • 5. Successful Treatment of Non-Small Cell Lung Cancer With Erlotinib Throughout Pregnancy.
    Ji Y; Schwartz J; Hartford A; Ramsey J; Phillips J; Verschraegen C
    JAMA Oncol; 2015 Sep; 1(6):838-40. PubMed ID: 26181671
    [No Abstract]   [Full Text] [Related]  

  • 6. NICE guidance on erlotinib for first-line treatment of EGFR-TK mutation-positive advanced or metastatic non-small-cell lung cancer.
    Dillon B; Naidoo B; Knight H; Clark P
    Lancet Oncol; 2012 Aug; 13(8):764-5. PubMed ID: 23024988
    [No Abstract]   [Full Text] [Related]  

  • 7. [Not Available].
    López-Brea M
    Med Clin (Barc); 2016 Apr; 146 Suppl 1():1. PubMed ID: 27426240
    [No Abstract]   [Full Text] [Related]  

  • 8. Targeted therapy for the treatment of non-small cell lung cancer: focus on inhibition of epidermal growth factor receptor.
    Harichand-Herdt S; Ramalingam SS
    Semin Thorac Cardiovasc Surg; 2008; 20(3):217-23. PubMed ID: 19038731
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Molecular selection trumps clinical selection.
    Shepherd FA
    J Clin Oncol; 2011 Jul; 29(21):2843-4. PubMed ID: 21670452
    [No Abstract]   [Full Text] [Related]  

  • 10. Role of tyrosine kinase inhibitors in lung cancer.
    Ansari J; Palmer DH; Rea DW; Hussain SA
    Anticancer Agents Med Chem; 2009 Jun; 9(5):569-75. PubMed ID: 19519298
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Resistant mechanism and treatment strategy of tyrosine kinase inhibitors].
    Qiao J; Chen W
    Zhongguo Fei Ai Za Zhi; 2011 Oct; 14(10):806-10. PubMed ID: 22008111
    [No Abstract]   [Full Text] [Related]  

  • 12. Differential responses to erlotinib in epidermal growth factor receptor (EGFR)-mutated lung cancers with acquired resistance to gefitinib carrying the L747S or T790M secondary mutations.
    Costa DB; Schumer ST; Tenen DG; Kobayashi S
    J Clin Oncol; 2008 Mar; 26(7):1182-4; author reply 1184-6. PubMed ID: 18309959
    [No Abstract]   [Full Text] [Related]  

  • 13. Is FISH floating or still swimming in the lung cancer ocean?
    Cappuzzo F; Camidge DR; Varella-Garcia M
    Ann Oncol; 2011 Mar; 22(3):493-499. PubMed ID: 21292645
    [No Abstract]   [Full Text] [Related]  

  • 14. Mutations in the epidermal growth factor receptor tyrosine kinase may predict response to gefitinib in non-small-cell lung cancer.
    Clin Lung Cancer; 2004 May; 5(6):331-2. PubMed ID: 15217530
    [No Abstract]   [Full Text] [Related]  

  • 15. [Mechanism of action and preclinical development of afatinib].
    Diz Taín P; González AL; García-Palomo A
    Med Clin (Barc); 2016 Apr; 146 Suppl 1():7-11. PubMed ID: 27426242
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Medical treatment of non-small-cell lung cancer.
    Buter J; Giaccone G
    Ann Oncol; 2005; 16 Suppl 2():ii229-32. PubMed ID: 15958463
    [No Abstract]   [Full Text] [Related]  

  • 17. Targeted therapies: Tyrosine-kinase inhibitors--new standard for NSCLC therapy.
    Saijo N
    Nat Rev Clin Oncol; 2010 Nov; 7(11):618-9. PubMed ID: 20981125
    [No Abstract]   [Full Text] [Related]  

  • 18. EGFR mutations in non-small cell lung carcinomas may predict response to gefitinib: extension of an emerging paradigm.
    Chang KL; Lau SK
    Adv Anat Pathol; 2005 Mar; 12(2):47-52. PubMed ID: 15731572
    [No Abstract]   [Full Text] [Related]  

  • 19. Epidermal growth factor receptor gene copy number and protein level are not associated with outcome of non-small-cell lung cancer patients treated with chemotherapy.
    Dziadziuszko R; Holm B; Skov BG; Osterlind K; Sellers MV; Franklin WA; Bunn PA; Varella-Garcia M; Hirsch FR
    Ann Oncol; 2007 Mar; 18(3):447-52. PubMed ID: 17082511
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Toxicity associated with EGRF inhibition: review and key aspects in the management of afatinib].
    Taus Á
    Med Clin (Barc); 2016 Apr; 146 Suppl 1():30-5. PubMed ID: 27426246
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.